Abstract
Romiplostim is a thrombopoietin-receptor agonist approved to treat chronic immune thrombocytopenia (ITP). We treated eight patients with acute or persistent primary ITP, severe clinical bleeding, and resistance to corticosteroids and/or intravenous immunoglobulins (IVIg). Romiplostim, initially administered at 2 or 3 μg/kg/week, was subsequently increased to achieve and maintain platelet-count responses and control bleeding. Seven patients’ platelet counts rose above 30 G/L, representing ≥twofold increases, within a median of 14 days after 1–5 infusions. The weekly dose reached 9 μg/kg at week 5 for three patients; the other patients’ ITPs were controlled with ≤6 μg/kg/week. No thromboembolic events occurred. Five patients received rituximab concomitantly with romiplostim, four of whom could stop romiplostim within 2 months, thereby demonstrating rituximab efficacy. All three patients treated with romiplostim alone required maintenance therapy. Thus, romiplostim represents an alternative for patients with severe acute or persistent ITP refractory to conventional therapy.



Similar content being viewed by others
References
Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113:2386–93.
Cooper N, Bussel J. The pathogenesis of immune thrombocytopenic purpura. Br J Haematol. 2006;133:364–74.
Aledort LM, Hayward CP, Chen MG, Nichol JL, Bussel J, ITP Study Group. Prospective screening of 205 patients with ITP, including diagnosis, serological markers, and the relationship between platelet counts, endogenous thrombopoietin, and circulating antithrombopoietin antibodies. Am J Hematol. 2004;76:205–13.
McMillan R, Wang L, Tomer A, Nichol J, Pistillo J. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood. 2004;103:1364–9.
Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115:168–86.
Khellaf M, Michel M, Schaeffer A, Bierling P, Godeau B. Assessment of a therapeutic strategy for adults with severe autoimmune thrombocytopenic purpura based on a bleeding score rather than platelet count. Haematologica. 2005;90:829–32.
Godeau B, Porcher R, Fain F, Lefrere F, Fenaux P, Cheze S, et al. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study. Blood. 2008;112:999–1004.
Tagariello G, Sartori R, Radossi P, Maschio N, Risato R, Stasi R. Romiplostim for the early management of severe immune thrombocytopenia unresponsive to conventional treatment. Br J Haematol. 2012;157:256–8.
Cantoni N, Heizmann M, Bargetzi M. Immune thrombocytopenia and anticoagulation: the role of romiplostim in the early treatment. Br J Haematol. 2012;157:639–41.
Mitsuhashi K, Ishiyama M, Imai Y, Shiseki M, Mori N, Teramura M, et al. Combined romiplostim and intravenous immunoglobulin therapy increased platelet count, facilitating splenectomy in a patient with refractory immune thrombocytopenic purpura unresponsive to monotherapy. Br J Haematol. 2012;158:798–800.
Kuter DJ, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB, Senecal FM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet. 2008;371:395–403.
Shirasugi Y, Ando K, Miyazaki K, Tomiyama Y, Okamoto S, Kurokawa M, et al. Romiplostim for the treatment of chronic immune thrombocytopenia in adult Japanese patients: a double-blind, randomized phase III clinical trial. Int J Hematol. 2011;94:71–80.
Andemariam B, Psaila B, Bussel JB. Novel thrombopoietic agents. Hematology Am Soc Hematol Educ Program. 2007:106–13.
Kuter DJ. Thrombopoietin and thrombopoietin mimetics in the treatment of thrombocytopenia. Annu Rev Med. 2009;60:193–206.
Gardiner EE, Thom JY, Al-Tamani M, Hughes A, Berndt MC, Andrews RK, et al. Restored platelet function after romiplostim treatment in a patient with immune thrombocytopenic purpura. Br J Haematol. 2010;149:625–8.
Conflict of interest
JFV has participated in advisory boards and Amgen and Glaxo SmithKline symposia (honoraria of less than 10,000 USD).
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Contis, A., Lazaro, E., Greib, C. et al. Romiplostim as early treatment for refractory primary immune thrombocytopenia. Int J Hematol 98, 520–524 (2013). https://doi.org/10.1007/s12185-013-1439-0
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12185-013-1439-0